Comparison · NCT01598831-sae
ART-123 vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ART-123 vs Placebo: serious adverse events. Trial comparisons, record NCT01598831-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01598831-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.52 | 0.471 | 0.569 | wilson | |
| Risk in group 2 | 0.5 | 0.451 | 0.549 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0202 | -0.0489 | 0.089 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.908 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.822 | 1.43 | log | |
| Number needed to harm, for one more participant with a serious adverse event on ART-123 than on Placebo | 49.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ART-123 | ART-123 (human recombinant thrombomodulin, thrombomodulin alfa) Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days | 206 | 396 | EG000 |
| Group 2 | Placebo | Placebo Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days | 202 | 404 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse events were collected between randomization and through Day 28 only. SAEs were collected from the time of authorization to randomize the participants until Day 28. All-cause mortality were collected as Fatal SAEs between randomization and Day 28 (End of Study) and as survival follow-up from Day 28 until 12 months.
Source ClinicalTrials.gov
Trial
- Title
- Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
- NCT number
- NCT01598831
- Phases
- PHASE3
- Conditions
- Severe Sepsis, Coagulopathy
- Interventions
- ART-123, Placebo
- Lead sponsor
- Asahi Kasei Pharma America Corporation
- Results first posted
- 2020-04-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01598831?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01598831-sae